Study Supports Role Of Anticort In Treating Alzheimer's, HIV
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Study Supports Role Of Anticort In Treating Alzheimer's, HIV

LAS VEGAS, NV -- April 17, 1998 -- New study results show that Steroidogenesis Inhibitors International’s Anticort(TM), the world's first drug designed expressly to reduce elevated levels of the stress hormone cortisol, may be effective in treating Alzheimer’s, other age-related diseases and AIDS.

Cortisol's role as a cause of disease is most recently confirmed in a study to be published in the May issue of the journal Nature Neuroscience. Authored by Dr. Sonia Lupien of McGill University, the study reports that high levels of cortisol play a key role in Alzheimer's, memory loss, shrinkage of the brain and aging. Dr. Lupien also states that such illnesses might be prevented with medications to reduce elevated cortisol levels.

Anticort is an anti-cortisol (steroidogenesis inhibitor) drug that prevents and treats the deadly immunosuppressive effects of elevated cortisol. When Dr. Sapse first began to evaluate Anticort's therapeutic potential, AIDS and Alzheimer's presented themselves as the two diseases most likely to be responsive. Due to the rapid spread of AIDS and the immense suffering associated with the fatal disease, Dr. Sapse decided to initially focus on HIV-positive patients.

A preliminary study of 60 HIV-positive patients in Brazil found Anticort to be effective in increasing CD4 (immune cell) counts and drastically reducing mortality. After submitting a comprehensive clinical program, STGI has received FDA approval to begin clinically testing Anticort on HIV-positive patients under a Phase IB/IIA setting.

Anticort's effectiveness in the treatment of Alzheimer's is equally promising. The drug reduces both cortisol and cholinesterase -- an enzyme responsible for destroying the key neurotransmitter acetylcholine. The McGill study serves as a strong catalyst to begin testing Anticort for the treatment of Alzheimer's patients. The company is planning to begin such tests later this year.

More information on: Anticort and Steroidogenesis Inhibitors International.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities